Preclinical Development of SCP-123 for Neuropathic Pain

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,901,765.00
Award Year:
2007
Program:
SBIR
Phase:
Phase II
Contract:
2U44NS046891-02
Award Id:
66674
Agency Tracking Number:
NS046891
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
650 Poydras St, Suite 2830, New Orleans, LA, 70130
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
603023529
Principal Investigator:
KENNETH NARDUCY
(408) 219-8748
KNARDUCY@MSN.COM
Business Contact:
KENNETH NARDUCY
() -
knarducy@msn.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Chronically, medically resistant pain is one of the most significant health problems in our country and affects more than 50 million Americans. Neuropathic pain syndromes are for the most part resistant to traditional analgesic treatments with NSAIDs, acetaminophen, or opiate medications (eg, morphine, codeine). Furthermore, most therapeutics currently used to treat neuropathic pain, including some antidepressants (eg, amitriptyline) and anticonvulsants (eg, gabapentin) , were not specifically developed for that purpose, and show efficacy in only a fraction of the patients. We have been exploring a series of new and proprietary acetaminophen analogs, in which the lead compound (SCP-1) and it's active metabolite (SCP-123) show a favorable safety profile and are active in rodent models of neuropathic pain. In the first year under this Phase II SBIR translational research project, we will evaluate both an oral solid and an intravenous (iv) solution of SCP-123 in three models of neuropathic pain and compare them to gabapentin. We will also evaluate the safety and pharmacokinetic profile of these two formulations. When these evaluations are complete, we will analyze the data and choose one of the formulations as a clinical candi date. In the second and third year of this grant we will conduct the preclinical studies (on the chosen formulation) that are necessary for an Investigative New Drug (IND) application to the FDA. At the end of the third year of this grant project, we will write and assemble the IND package and submit it to the FDA. If the FDA accepts the IND application, we will shortly thereafter begin the Phase I human clinical of SCP-123 Chronically, medically resistant pain is one of the most significant health problems in our country and affects more than 50 million Americans. Patients with neuropathic pain are often treated with medications from different drug classes including tricyclic antidepressants, anticonvulsants, topical agents, and opioids, but the use of thes e pharmacological agents is limited both because of lack of efficacy and/or the occurrence of undesirable side-effects. St Charles Pharmaceuticals is proposing to develop a new class of compounds that have activity in neuropathic pain models and hold the p romise of addressing the shortcomings of current treatments.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government